ProShares Ultra Nasdaq Biotechnology


ProShares Ultra Nasdaq Biotechnology

  • Price (USD)61.66
  • Today's Change-0.31 / -0.50%
  • Shares traded190.71k
  • 1 Year change49.62%
Data delayed at least 15 minutes, as of Oct 19 2017 21:00 BST.
More ▼

Profile and investment

Fund typeOpen Ended Investment Company
Investment style (stocks)Market Cap: Mid
Investment Style: Growth
Morningstar categoryTrading--Leveraged Equity
Launch date06 Apr 2010
Price currencyUSD
DomicileUnited States
Manager & start date
Michael Neches
01 Oct 2013
Devin Sullivan
30 Sep 2016
Pricing frequencyDaily
Total net assets
486.82m USD
As of Sep 30 2017
Net expense ratio0.95%
Front end load--
Deferred load--
Redemption fee--
Min. initial investment--
Min. additional investment--
Initial IRA--
Additional IRA--
Available for saleUnited States
More ▼

Top 5 holdings

Top 5 holdings as a per cent of portfolio
Category average% Net assets% Short% Long
Company1 year changePortfolio weightLong allocation
Nasdaq Biotechnology Index Swap Bank Of America Na--38.95%
Ishares Biotech (Ibb) Swap Bank Of America Na--27.47%
Nasdaq Biotechnology Index Swap Societe Generale--23.26%
Nasdaq Biotechnology Index Swap Credit Suisse International--14.66%
Nasdaq Biotechnology Index Swap Ubs Ag--8.29%
Per cent of portfolio in top 5 holdings: 112.63%


Asset type

Asset type

US stock73.57%
Non-US stock1.20%
US bond0.00%
Non-US bond0.00%

Top 5 sectors

Fixed income

Top 5 regions

United States72.14%
United Kingdom0.36%
Emerging Asia0.27%
Middle East0.04%
Sector and region weightings are calculated using only long position holdings of the portfolio.
Intra-day ETF pricing data provided by
© Thomson Reuters Click for restrictions
The performance data shown in tables and graphs on this page is calculated in USD of the fund/index/average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ex-dividend date. Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.
All managed funds data located on is subject to the FT Terms & Conditions
All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All data shown on this page, unless noted otherwise is Data Source and Copyright: Morningstar, Inc. 2017
All Rights reserved
© 2017 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.